Biology is slower and more varied than marketing copy, so a slow plan can still be a good plan
It is essential for maintaining cellular health and combating oxidative stress
GLP-1 receptor agonists may be appropriate for individuals who: Have a body mass index (BMI) of 35 kg/m or higher (or lower thresholds32.5 kg/m or abovefor people from Black, Asian, and other minority ethnic groups) and would benefit from weight loss Have established cardiovascular disease or are at high cardiovascular risk (certain GLP-1 receptor agonists have demonstrated cardiovascular benefits in clinical trials) Have chronic kidney disease (CKD) or heart failure, where specific agents may offer additional protection Require additional glucose-lowering therapy but wish to avoid weight gain associated with some other diabetes medicines Cannot tolerate or have contraindications to other glucose-lowering therapies NICE NG28 continuation criteria : GLP-1 receptor agonist therapy should be continued beyond 6 months only if the person has had a beneficial metabolic response , defined as a reduction of at least 11 mmol/mol (1.0%) in HbA1c and a weight loss of at least 3% of initial body weight
What documentation is required to demonstrate program compliance and non-response
Commonly reported symptoms of menopause include hot flashes, night sweats, vaginal dryness, sleep disturbances, mood swings and weight gain, 1 with an estimated 70% of menopausal women experiencing weight gain
However, the development of mRNA-based drugs has resulted in several challenges
,aspect=ignore)
